Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 381.5 JPY 2.12% Market Closed
Market Cap: ¥562.5B

Rohto Pharmaceutical Co Ltd's latest stock split occurred on Dec 29, 2022

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

Before the split, Rohto Pharmaceutical Co Ltd traded at 2397.5 per share. Afterward, the share price was about 2343.

The adjusted shares began trading on Dec 29, 2022. This was Rohto Pharmaceutical Co Ltd's 2nd stock split, following the previous one in Sep 27, 2005.

Last Splits:
Dec 29, 2022
2-for-1
Sep 27, 2005
2-for-1
Pre-Split Price
2 397.5 2 397.5
Post-Split Price
2 343
Before
After
Last Splits:
Dec 29, 2022
2-for-1
Sep 27, 2005
2-for-1

Rohto Pharmaceutical Co Ltd
Stock Splits History

Rohto Pharmaceutical Co Ltd Stock Splits Timeline
Dec 29, 2022
Dec 29, 2022
Split 2-for-1
x2
Pre-Split Price
2 397.5 2 397.5
Post-Split Price
2 343
Before
After
Sep 27, 2005
Sep 27, 2005
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
810.2189
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 24, 2026
Cue Biopharma Inc
NASDAQ:CUE
1-for-30
/30
0.5542 16.626 USD 17.695 17.695 USD
Apr 24, 2026
Medical Data Vision Co Ltd
TSE:3902
2-for-7253607
/3626803.5
1684 1684 JPY N/A
Apr 24, 2026
E
ESGL Holdings Ltd
NASDAQ:ESGL
1-for-3
/3
2.35 7.05 USD 2.93 2.93 USD
Apr 24, 2026
Metro Mining Ltd
ASX:MMI
1-for-20
/20
0.067 1.34 AUD 1.3 1.3 AUD
Apr 24, 2026
L
La Comer SAB de CV
OTC:LCMRF
115-for-114
x1.0087719298246
2.4715 2.4341 USD 2.45 2.45 USD
Load More

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
562.5B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
2 162.98 JPY
Overvaluation 9%
Intrinsic Value
Price ¥2 381.5
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett